Results 161 to 170 of about 21,234 (200)

Progressive multifocal leukoencephalopathy

Journal of Neuroimmunology, 2011
Progressive multifocal leukoencephalopathy (PML) is a disease of the central nervous system (CNS) with destructive infection of oligodendrocytes by JC virus. PML belongs to the opportunistic infections. It is observed in patients with HIV infection, lymphoid malignancies, after organ- and stem cell transplantations and more recently in the context of ...
Maria G. Chiara, Eugene O. Major
openaire   +3 more sources

Progressive Multifocal Leukoencephalopathy

Seminars in Neurology, 1999
Before the AIDS epidemic, progressive multifocal leukoencephalopathy (PML) was a rare disorder occurring most often in association with leukemia and lymphoma. Current estimates indicate that PML ultimately develops in up to 5% of all patients with AIDS.
J R, Berger, E O, Major
openaire   +4 more sources

Progressive Multifocal Leukoencephalopathy

European Neurology, 1971
The present paper reports on a case of progressive multifocal leukoencephalopathy, with certain particularities.
C, Arseni, F, Nerean tiu
openaire   +4 more sources

Progressive multifocal leukoencephalopathy

Current Infectious Disease Reports, 2001
Progressive multifocal leukoencephalopathy is a subacute demyelinating disease that occurs in patients with defects in cell-mediated immunity, including those with AIDS and lymphoproliferative disorders. It is caused by reactivation of JC virus (JCV), which infects 70% to 90% of the population by adulthood, but remains latent in normal hosts.
Anna R., Thorner, Joel T., Katz
openaire   +3 more sources

Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients

Multiple Sclerosis, 2020
Dimethyl fumarate (DMF), a fumaric acid with antioxidant and immunomodulatory properties, is among the most commonly used oral therapies for relapsing multiple sclerosis (MS).
Allison Jordan, Jennifer Yang, Caitlyn J Fisher, M. Racke, Y. Mao-Draayer   +4 more
semanticscholar   +1 more source

Progressive Multifocal Leukoencephalopathy

Archives of Internal Medicine, 1963
Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating disease apparently resulting from the selective destruction of oligodendrocytes by papovaviruses. The pathology and pathogenesis of PML are distinct from those of the other slow infections of the human nervous system.
R F, JOHNSTON, R A, GREEN, J T, HEADINGTON   +2 more
openaire   +2 more sources

Progressive Multifocal Leukoencephalopathy

Radiology, 1976
The radionuclide, radiographic and pathologic findings in a patient with progressive multifocal leukoencephalopathy were correlated. Radionuclide imaging demonstrated the largest two of the many lesions observed at pathology. On repeated studies, one of the lesions developed a "doughnut" sign due to central necrosis. Cerebral angiography disclosed only
J, Kirsh, L, Rosenthall, M H, Finlayson, R, Wee   +3 more
openaire   +2 more sources

Progressive Multifocal Leukoencephalopathy

Archives of Ophthalmology, 1959
Astrom, Mancall, and Richardson1have recently directed attention to progressive multifocal leukoencephalopathy, a previously unrecognized neuropathological entity. Visual symptoms have been prominent in this disorder. As no cases have been reported in the ophthalmologic literature, the following instance of progressive multifocal leukoencephalopathy ...
openaire   +2 more sources

Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab.

New England Journal of Medicine, 2019
Treatment of PML with Nivolumab A patient with severe idiopathic lymphopenia and progressive multifocal leukoencephalopathy had T-cell exhaustion and high expression of immune checkpoint markers.
O. Walter, Emmanuel Treiner, F. Bonneville, C. Mengelle, F. Vergez, F. Lerebours, P. Delobel, R. Liblau, G. Martin-Blondel   +8 more
semanticscholar   +1 more source

Progressive multifocal leukoencephalopathy and anti‐CD20 monoclonal antibodies: What do we know after 20 years of rituximab

Reviews in Medical Virology, 2019
In 1997, rituximab was the first monoclonal antibody clinically approved for the treatment of cancer. Ten years later, progressive multifocal leukoencephalopathy (PML), until that time a rare opportunistic infection mostly seen in AIDS patients, was ...
D. Focosi, M. Tuccori, F. Maggi
semanticscholar   +1 more source